Eugenol, a potential schistosomicidal agent with anti-inflammatory and antifibrotic effects against Schistosoma mansoni, induced liver pathology [Corrigendum]
Infection and Drug Resistance
Dovepress
open access to scientific and medical research
Open Access Full Text Article
CORRIGENDUM
Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 88.198.20.149 on 30-Oct-2019
For personal use only.
Eugenol, a potential schistosomicidal agent with anti-inflammatory and
antifibrotic effects against Schistosoma mansoni, induced liver pathology
[Corrigendum]
El-kady AM, Ahmad AA, Hassan TM, et al. Infect Drug
Resist. 2019;12:709–719.
On page 709 in the abstract, in the Materials and methods
section should read “The murine model of S. mansoni was
established in four groups of adult male Balb-c mice;
group I (infected non-treated group), groups II and III
(infected groups) treated orally with eugenol and praziquantel (PZQ), respectively and group IV (non-infected
non treated group). The expression of the sensitive immunohistochemical marker α-smooth muscle actin (α-SMA)
in schistosome-infected tissues was determined. In addition, parasitological, biochemical, and histological parameters that reflect disease severity and morbidity were
examined.”
On page 710, the section headed Animals and experimental design, should read “Thirty two adult male
Balb-c mice, weighing 18–20 g each, were obtained
from the Schistosome Biological Supply Program at
Theodor Bilharz Research Institute, Imbaba, Giza,
Egypt. Mice were infected percutaneously with approximately 100±2 S. mansoni cercariae by the paddling
method.31 The animals were given access to water and
a standard diet, and the health status of the animals was
monitored daily.”
On page 710, the section headed Experimental design, should
read “The mice were divided into four groups, with eight mice
per group as follows; group I was a positive control (infected
with S. mansoni cercariae but non-treated); group II was
infected with S. mansoni cercariae and treated with eugenol;
group III was infected with S. mansoni cercariae and treated
with PZQ; and group IV was a negative control (uninfected
untreated group). All mice were sacrificed at the end of the
eighth week postinfection.”
On page 714 the legend for Figure 3 was incorrect. The
correct figure legend should read:
Figure 3 Photomicrographs of the liver stained with
H&E.
Notes: (A) control group, showing normal portal triad
along with a normal hepatocytes and the central vein
(×100). (B) Infected untreated group, showing numerous
granulomas with bilharzial ova surrounded by numerous
chronic inflammatory cells (×100). (C and D) Higher
power view showed numerous bilharzial ova containing
meracedium and brownish black bilharzial pigmentation
and hydropic degeneration in hepatocytes (×400). (E) PZQ
treated group. (F) Eugenol treated group, showing reduced
size and number of granuloma and decreased amount of
bilharzial ova and the chronic inflammatory cells with
absence of hydropic changes in hepatocytes (×100).
On page 716 the legend for Figure 5 was incorrect. The
correct figure legend should read:
Figure 5 Photomicrographs of the liver stained immunohistochemially with α-SMA.
Notes: (A) The control group showing negative expression of α-SMA staining (×100). (B, C, and D) Infected
untreated control groups showing intense immune-positive
reaction of α-SMA in the central and portal tract area as
well as around granulomas (B ×100, C and D ×400). (E)
PZQ treated groups and (F) Eugenol treated groups showing a reduction in the amount of α-SMA compared with
the infected, untreated control group (×400).
2003
submit your manuscript | www.dovepress.com
Infection and Drug Resistance 2019:12 2003–2004
DovePress
© 2019 El-kady et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://doi.org/10.2147/IDR.S216525
Powered by TCPDF (www.tcpdf.org)
On page 71, the section headed Evaluation of pathological
changes using H&E stained sections; the sentence “. . . cell
cords were separated by narrow blood sinusoids lined by
endothelial cells (Figure 1).” Should read “. . . cell cords
were separated by narrow blood sinusoids lined by
endothelial cells (Figure 3).”
Dovepress
Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 88.198.20.149 on 30-Oct-2019
For personal use only.
El-kady et al
Infection and Drug Resistance
Dovepress
Publish your work in this journal
Infection and Drug Resistance is an international, peer-reviewed openaccess journal that focuses on the optimal treatment of infection
(bacterial, fungal and viral) and the development and institution of
preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of
antibiotic resistance and the mechanisms of resistance development and
diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peerreview system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/infection-and-drug-resistance-journal
2004
Powered by TCPDF (www.tcpdf.org)
submit your manuscript | www.dovepress.com
DovePress
Infection and Drug Resistance 2019:12
(...truncated)
